Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rated “Equal Weight” in New Coverage at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report released on Wednesday. The brokerage issued an equal weight rating and a $5.00 price target on the stock.

Other equities analysts have also issued research reports about the stock. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 target price on the stock. William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “outperform” rating for the company. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Rodman & Renshaw assumed coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.75.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $2.52 on Wednesday. The company has a market capitalization of $180.61 million, a price-to-earnings ratio of -1.29 and a beta of 1.93. The business has a 50 day moving average of $3.75 and a 200 day moving average of $3.86. Zentalis Pharmaceuticals has a 1-year low of $1.21 and a 1-year high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.11 EPS for the current year.

Insider Activity

In other news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the purchase, the insider owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. The trade was a 32.09% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.80% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently modified their holdings of the business. Spark Investment Management LLC bought a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $61,000. Susquehanna Fundamental Investments LLC purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $126,000. Stonepine Capital Management LLC purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $783,678. Seven Fleet Capital Management LP grew its position in shares of Zentalis Pharmaceuticals by 188.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock worth $1,451,000 after buying an additional 207,600 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $5,406,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to address biological mechanisms involved in tumor growth, resistance to treatment and disease progression.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral, selective WEE1 kinase inhibitor. The company is evaluating azenosertib in clinical studies involving solid tumors and hematologic malignancies, including ovarian cancer, uterine serous carcinoma and other cancers.